New Jersey 2024-2025 Regular Session

New Jersey Senate Bill S729

Introduced
1/9/24  
Introduced
1/13/26  
Refer
1/9/24  
Refer
1/13/26  

Caption

Establishes tianeptine as Schedule II controlled dangerous substance.

Impact

Upon enactment, S729 is expected to significantly improve the procedures State agencies must follow when adopting rules and regulations. The enhancements in public engagement and transparency could lead to more informed decision-making and stronger regulatory outputs, aligning them more closely with the needs and expectations of New Jersey residents. Moreover, the legislation emphasizes the necessity for agencies to evaluate and report on the socio-economic implications of proposed rules, including potential impacts on state and local expenditures as well as how they may affect citizens and businesses.

Summary

S729 proposes several modifications to the provisions of the Administrative Procedure Act, highlighting a commitment to enhance transparency and public engagement in state agency rule-making processes. Key changes include extending the public comment period from 30 to 60 days, mandating agencies to publicly share all comments and data related to proposed rules, and requiring a clearer justification for rule proposals. Furthermore, the bill establishes that if there is sufficient public interest, as indicated by at least 50 comments requesting an extension or public hearing, agencies must grant such requests, thus ensuring that citizens have a greater voice in governance.

Sentiment

The overall sentiment surrounding S729 appears to be positive among proponents who value increased public engagement and transparency in government processes. Supporters argue that these changes will strengthen democracy by allowing citizens to have a greater influence on administrative decisions. However, there may also be concerns from some local state agencies regarding their capacity to manage the increased requirements and the potential for extended procedural timelines. Opposition may focus on worries that these changes could slow down necessary regulatory actions.

Contention

Notable points of contention involve discussions on the balance between regulatory efficiency and public engagement. Critics might express concern that the increased comment period and procedural requirements could result in delays in implementing necessary rules. Additionally, there may be debate on how 'sufficient public interest' is defined and whether the thresholds set by the bill will effectively capture the voice of the community. As the bill moves forward, stakeholders will need to navigate these challenges to ensure that enhanced public participation does not hinder the timely functioning of state agencies.

Companion Bills

NJ A4814

Replaced by Establishes tianeptine as Schedule II controlled dangerous substance.

NJ S3668

Carry Over Establishes tianeptine as Schedule II controlled dangerous substance.

NJ A5461

Carry Over Allows municipalities to transfer inactive alcoholic beverage retail licenses for use in redevelopment areas under certain circumstances; allows retail distribution and seasonal consumption licenses to be converted into consumption licenses.

Previously Filed As

NJ S322

Establishes tianeptine as Schedule II controlled dangerous substance.

NJ S01720

Adds tianeptine sodium to list of Schedule II of controlled substances.

NJ S03351

Adds tianeptine sodium to list of Schedule II of controlled substances.

NJ A07501

Adds tianeptine sodium to list of Schedule II of controlled substances.

NJ S2036

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

NJ A864

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

NJ HB3767

Controlled dangerous substances; adding certain substances to Schedules I and IV; effective date.

NJ SB946

Further providing for schedules of controlled substances and providing for tianeptine-related adverse health events.

NJ HB0417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

NJ S1865

Adds illicit fentanyls to Schedule I in the "New Jersey Controlled Dangerous Substances Act."

Similar Bills

No similar bills found.